Literature DB >> 233366

Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.

S L Swartz, G H Williams, N K Hollenberg, T J Moore, R G Dluhy.   

Abstract

To determine the relative importance of hormonal factors in mediating the hypotensive response to converting enzyme inhibition (CEI), plasma renin activity (PRA), angiotensin II, and bradykinin responses to SQ20,881 were measured in 20 supine patients with essential hypertension in balance on a 10 mEq sodium diet. Patients were divided into two groups according to their diastolic blood pressure response: responders had a decrement in diastolic pressure which exceeded 9 mm Hg, the upper value of the 95% confidence limits for normotensive patients studied under similar conditions; nonresponders did not. Compared to the nonresponders, responders not only had a higher control PRA (8.7 +/- 1.7 ng/ml/hr vs 4.8 +/- 2.1, p < 0.05) and larger decrement in plasma angiotensin II (18.7 +/- 4.9 pg/ml vs 3.2 +/- 1.7, p < 0.01), but also had a higher control bradykinin (3.2 +/- 0.7 ng/ml vs 1.1 +/- 0.2, p < 0.05) and larger increment in bradykinin (4.5 +/- 1.3 ng/ml vs 1.0 +/- 0.4, p < 0.05) following SQ20,881. Because SQ20,881 altered both angiotensin II and bradykinin concentrations, we assessed the contribution of blockade of angiotensin II formation by administering angiotensin II infusions to seven responders during coverting enzyme blockade, with the angiotensin II dose adjusted to restore diastolic pressure to control levels. The plasma angiotensin II level required to return blood pressure to control was 45 +/- 15 pg/ml higher than the control plasma angiotensin II level (p < 0.01), suggesting that some other factor(s), perhaps bradykinin, are also responsible for the hypotensive response to converting enzyme inhibition.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 233366     DOI: 10.1161/01.hyp.1.2.106

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  21 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Inhibitors of angiotensin I converting enzyme for treating hypertension.

Authors: 
Journal:  Br Med J       Date:  1980-09-06

3.  Converting enzyme inhibitors in hypertension and heart failure.

Authors:  H J Dargie; S G Ball; A B Atkinson; J I Robertson
Journal:  Br Heart J       Date:  1983-04

4.  Haemodynamic profile of captopril treatment in various forms of hypertension.

Authors:  J H de Bruyn; A J Man in't Veld; G J Wenting; F H Derkx; M A Schalekamp
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus.

Authors:  P Weidmann
Journal:  Klin Wochenschr       Date:  1980-10-01

Review 6.  Endocrine physiology of electrolyte metabolism.

Authors:  K G Dawson
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

7.  Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.

Authors:  A Overlack; K O Stumpe; M Kühnert; R Kolloch; C Ressel; I Heck; F Krück
Journal:  Klin Wochenschr       Date:  1981-01-15

Review 8.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

9.  Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats.

Authors:  B Chauvin; C Richer; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.

Authors:  T Sakamoto; C Chen; M F Lokhandwala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.